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Abstract
The current situation, heavily influenced by the ongoing pandemic, puts vaccines back into the spotlight. However, the con-
ventional and traditional vaccines present disadvantages, particularly related to immunogenicity, stability, and storage of the 
final product. Often, such products require the maintenance of a “cold chain,” impacting the costs, the availability, and the 
distribution of vaccines. Here, after a recall of the mode of action of vaccines and the types of vaccines currently available, 
we analyze the past, present, and future of vaccine formulation. The past focuses on conventional formulations, the present 
discusses the use of nanoparticles for vaccine delivery and as adjuvants, while the future presents microneedle patches as 
alternative formulation and administration route. Finally, we compare the advantages and disadvantages of injectable solu-
tions, nanovaccines, and microneedles in terms of efficacy, stability, and patient-friendly design.
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Introduction
The challenging months of 2020 have brought to the 
forefront the critical issues associated with the discovery and 
formulation of effective treatments and, ultimately, a vaccine 
during epidemics and pandemics [1]. The emergence of a 
new type of respiratory coronavirus (severe acute respiratory 
syndrome, SARS, CoV, or 2019 novel CoV) and its growth 
in the present-day pandemic recall the previous two 
experiences with CoV, namely SARS-CoV and Middle 
East Respiratory Syndrome Coronavirus (MERS-CoV) 
[1, 2]. However, the development of effective vaccines for 
SARS-CoV or MERS-CoV was slowed or abandoned once 
the epidemic was controlled [3, 4]. The critical analyses 
on pandemic preparedness after the H1N1 pandemic 
highlighting the failure to distribute enough vaccines where 
they were needed, when they were needed, had not been 
implemented before the emergence of SARS-CoV2 [5]. 
This has caused a delay in the discovery and formulation 
of candidate vaccines for SARS-CoV2, requiring an 
unprecedented effort by public (academia and government 
bodies) and private (industrial) to fast track the development 
of vaccines [6].
The current pandemic highlighted also the challenges 
related to timely distribution of vaccines for seasonal flu or 
other diseases, together with the problematic “cold chain” 
[7]. These challenges are heavily dependent on the vaccine 
formulations and their features (Table 1), and thereby, on 
pharmaceutical technology research and innovations.
In this review, we will first introduce the immunological 
mechanisms at the base of vaccination, followed by a 
discussion on the classes of vaccines available. The main 
body of the article will analyze the past conventional 
formulations, the present solutions entertained by 
nanotechnology, and the future developments.
Immunological context of vaccination
The paradigm of vaccination is the creation of a long-
term immunization against one or more antigens specific 
for a pathogen or cancer cell through the development 
of antibodies and cytotoxic T cells. The process can be 
summarized into 3 steps: (1) uptake of antigens and adjuvants 
from antigen presenting cells (APCs), (2) maturation of the 
APCs, and (3) priming of antigen-specific B and T cells with 
the production of antibodies and cytotoxic T cells (Fig. 1) [8].
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APCs are immature dendritic cells, macrophages, B cells, 
or even immune fibroblasts, which can take-up antigens and 
are activated by endogenous or exogenous danger signals 
[9–11]. Upon activation, the APCs, particularly dendritic 
cells, assume a mature phenotype while processing the 
antigens into peptides suitable for the expression on major 
histocompatibility molecules (MHCs) I or II. At the same 
time, the APC is presenting co-stimulatory signals (e.g., 
CD80 or 86) and secreting proinflammatory cytokines [12]. 
Finally, naïve T cells interact with MHC and are primed 
into cytotoxic or helper T cells. B cells get activated upon 
interaction of their B cell receptor (BCR) with soluble or 
bound antigens, then leading to the differentiation into plasma 
or memory B cells and the production of antigen-specific 
antibodies [13]. Furthermore, the activation process can be 
dependent on the presence of helper T cells or independently 
for any other signal. Antibodies can fight a viral infection 
by attaching on the surface of the virus, creating steric 
hindrance, preventing viral infection in the cells, preventing 
the virus release from the infected cells, blocking the cleavage 
of hemagglutinin, activating complement, and flagging the 
virus to phagocytes for the elimination (Fig. 2) [14].
As for cytotoxic T cells, their role is to recognize and 
kill virus-infected or cancer cells, as well as to release 
interferon-γ and tumor necrosis factor-α [15, 16]. The type 
of vaccine, antigen, adjuvant, and route of administration 
chosen all have an effect on the type and magnitude of the 
immune response primed, as well as on the duration of the 
immunological memory.
Types of vaccines
Currently there are eight different classes of vaccines, 
distinct in origin, composition, and immunogenicity (Fig. 3).
Table 1  Comparison between 
the characteristics of the 
different vaccine formulations
Features Injections Microneedles Nanovaccines Oral solutions
Mode of administration Needle (Micro)needle Injection/inhalation Liquid oral solution
Onset Fast Fast Fast Slow
Self-administration No Yes No Yes
Storage conditions Cold chain Room temperature Formulation-dependent Cold chain
Pain Painful Painless Painful/Painless Painless
Patient compliance Poor Good Medium Very good
Safety Poor Good Good Good
Usability Moderate Good Moderate/Good Good
Fig. 1  Immune activation after vaccination. The antigens and adju-
vants contained in the vaccine formulation are taken-up by immature 
APC or B cell. The APC processes the signal and achieves a mature 
phenotype, further transmitting the signal to cytotoxic T cells, helper 
T cells, and B cells. The endpoint in a successful vaccination is the 
development of antigen-specific antibodies and cytotoxic T cells. Fig-
ure created from elements of Servier Medical Art, licensed under a 
Creative Commons Attribution 3.0 Unported License
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Live-attenuated vaccines are the first type of vaccines 
developed, and they have successfully eradicated smallpox, 
almost eradicated poliomyelitis, and contribute to control 
the worldwide cases of measles while being less effective for 
chronic infections [17]. Furthermore, this class of vaccines is 
associated with risks connected with the safety and efficacy 
of the vaccine. Live-attenuated vaccines either are usually 
closely related viruses that are not pathogenic for human, or 
less severe strains, or are obtained after repeated culturing 
in cells from a species not permissive for the virus [17]. 
Importantly, these vaccines are the only class not requiring 
any additional adjuvant to be co-administered. The safety 
concerns are related to possible reversion to virulent wild 
type [18]. Furthermore, these viruses are sensitive to 
storage conditions and demand a well-kept cold chain [19]. 
Inactivated or “killed” vaccines are prepared by inactivating 
the pathogen through heat, radiation, or use of chemical 
compounds (e.g., formalin) [20]. Inactivating means to 
destroy the ability of the virus to replicate in the human body 
while keeping all the antigens present in the viral structure 
[20]. A variety in the immune response according to the 
source of the antigen, the need for adjuvants, and the lower 
efficacy are the downsides of this class of vaccines.
The third class of vaccines in order of discovery is 
toxoids [21]. Toxoid vaccines are prepared from the toxins 
secreted from bacteria (e.g., tetanus and diphtheria). It is a 
mature technology, and vaccines for tetanus and diphtheria 
are commonly administered worldwide. They are not highly 
Fig. 2  Mode of action of antibodies against viruses. The seven different mechanisms by which antibodies can block a viral infection (the exam-
ples in the figure refers to flu).  Reproduced with permission from ref. [14]
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immunogenic, and they require the formulation with an 
adjuvant, as well as multiple administrations. However, they 
show an excellent stability profile [22]. Starting from 1970, 
the use of modern technologies in microbiology allowed 
for the isolation of carbohydrate-based vaccines, which are 
mainly targeting the bacterial capsule polysaccharides, but 
also viruses and cancer, and are nowadays produced from 
synthetic methods to obtain homogenous glycans [23]. In order 
to increase their immunogenicity, particularly in children, 
they are often conjugated to a carrier protein [23]. Conjugated 
vaccines are formed by the conjugation of a protein to a 
carbohydrate to increase its immunogenicity and stability 
[24]. Often, they are classified together with the carbohydrate 
antigens. They can be conjugated to toxoids from tetanus.
Recombinant vector vaccines are produced by inserting the 
sequence coding for the desired antigen from a pathogen inside 
another vector as foreign transgene [25]. This type of vaccine 
shows good immunogenicity. However, the presence of a 
foreign transgene in the vector genome may lead to evolutionary 
mutations that decrease the immunogenicity and thereby the 
efficacy of the vaccine [25]. Subunit vaccines are composed 
by protein immunogens, or antigens, usually produced through 
recombinant technologies [26]. They show an excellent safety 
profile and can be modified to change properties facilitating the 
development of stable formulations. However, the downside 
is their limited immunogenicity when compared with live-
attenuated vaccines. Thereby, they often require the formulation 
together with adjuvants, to increase their efficacy [26].
Finally, nucleic acid–based vaccines have been 
developed in the past 30 years, with strong hype on their 
good stability and fast production, safety profile compared 
with live-attenuated viruses, not inducing neutralizing 
antibodies, and ensuring that the immune response is 
directed against the transgene product and not partially 
against the viral coating [27, 28]. mRNA-based vaccines 
are currently approved as vaccines for SARS-CoV2 
(Moderna, Pfizer/BioNTech) [29].
A considerate analysis of formulation from a pharmaceutical 
technology perspective is deemed essential to provide the 
best characteristics to the vaccine in terms of efficacy, but 
also manufacturing, storing, and distribution [30]. In this 
review, we are presenting three different approaches to 
vaccine formulation development, the conventional vaccine 
formulations from the past, the current development of lipid 
nanoparticles as vaccines (e.g., Moderna and CureVac), and 
the near-future microneedle formulations.
Fig. 3  Classes of vaccines, their 
main advantages, and disad-
vantages. Figure created from 
elements of Servier Medical 
Art, licensed under a Crea-
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Past: conventional vaccine formulations
Conventional vaccine formulations have shaped the world, 
contributing to the eradication of small pox, and to control 
other infective diseases (e.g., measles, mumps, tetanus). 
Most of us have been vaccinated at some point in life; usu-
ally, we routinely get tetanus vaccine rechallenge, and we 
get a yearly vaccination to protect us from the new strains 
of flu. The conventional vaccine formulations are effective 
mainly against pathogens which conserve their antigenic 
profile (e.g., measles and mumps)[21]. A lower efficacy 
and the need to widen the antigenic content of the vaccine 
or administer new vaccines every year are found for highly 
mutant pathogens (e.g., influenza virus and pneumococ-
cus). Finally, the major concern about conventional vac-
cines is their inefficacy toward pathogens that change their 
antigens after their infection (HIV). Furthermore, conven-
tional vaccines and the adjuvants used in the formulations 
are mainly directed to elicit a humoral, B cell-mediated, 
immune response. However, in multiple cases, either B 
cells alone are not enough to handle the pathogen and need 
support from helper T cells or the pathogen infection and 
residence site are intracellular, requiring cytotoxic T cells 
for its elimination [21]. Importantly, current vaccines, par-
ticularly the ones administered to elderly population, are 
gender-biased; the efficacy of such vaccinations (flu and 
pneumococcus to begin with) is higher in women than 
men, a worrying factor, considering that SARS-CoV2 is 
more severely affecting men [31, 32]. The current situ-
ation, with the ongoing pandemic of SARS-CoV2, has 
highlighted once again the importance of having an 
effective vaccination to immunize the general population 
worldwide.
Conventionally administered vaccines are mostly 
administered through injection, intramuscular, subcuta-
neous, or intradermal [33]. Thereby, they usually require 
specific conditions for the transport and storage [33]. The 
formulation process is thereby based on the preparation of 
solid powder to be reconstituted before use. The two main 
focuses in the formulation development for vaccines are 
the stability of the final product, which will influence the 
storage conditions, and the addition of adjuvants, of par-
ticular interest in subunit, carbohydrate, or toxoid-based 
vaccines to increase their immunogenicity.
Despite the successes achieved in controlling smallpox 
and other diseases, there are some limitations associated 
with conventional vaccines, demonstrating the need for 
better and safer vaccines.
Adjuvants for preparation of vaccines
As for the adjuvants, regulatory authorities have specific 
guidelines regulating the selection and quality control of 
the adjuvant, including assays to evaluate the stability of 
the adjuvant alone and of the adjuvant-antigen complex 
[34]. Furthermore, the adjuvant alone and the final formu-
lation should go through extensive preclinical and clinical 
assessment of safety and efficacy, measured in the ability 
to stimulate the immune system against the pathogen [34]. 
The list of adjuvants approved from the regulatory agen-
cies includes 9 adjuvants [35]. The most used adjuvant 
is alum, made of particulate aluminum salts, which form 
a depot in the site of administration. The exact mode of 
action of alum is still investigated and includes multiple 
pathways [35]: the presentation of the antigen on an alum 
particle improves the interaction with APCs; alum itself 
can interact with lipids on APCs membrane, activating 
the cells, and alum activates inflammasome, resulting into 
activation of innate immunity. Alternatively, oil-in-water 
emulsions (e.g., MF59) do not directly interact with APCs 
but modify the immune contexture surrounding the admin-
istration spot facilitating the migration of APCs [36]. The 
size of the emulsion droplet is of the utmost importance 
for the efficacy of the vaccination; too small particles have 
lower efficacy than 160 nm droplets [36]. Monophosphoryl 
lipid A (MPLA) derives from bacteria and activates toll-
like receptor 4. MPLA is nowadays produced as synthetic 
analogue by synthesis instead of relying on the extrac-
tion from bacteria [35]. Saponins are natural molecules 
extracted from plants and are usually combined with cho-
lesterol to lower their toxicity. They increase the uptake of 
the antigen by APCs by interacting with cholesterol-rich 
areas on the cell membrane of APCs. Finally, virosomes, 
used for flu vaccines, are made of liposomes with structure 
resembling a virus, due to their formulation from empty 
virus particles (usually from influenza virus) [35]. Other 
types of adjuvants are currently in clinical development, 
including DNA sequences as CpG, polyelectrolytes, and 
outer membrane vesicles derived from bacteria [35].
Stability aspects of vaccines
The main disadvantage of conventional vaccines, the storage 
requirements including cold chain, impacts both the world-
wide distribution and the stockpiling [37]. Different vaccine 
formulations exhibit different stabilities to temperature, as 
summarized in ordinal scale in Fig. 4.
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In particular, liquid formulations, with or without 
adjuvants, are more sensitive to damage from freezing; 
thereby, they need a carefully controlled refrigeration. On 
the contrary, the type of vaccine (inactivated, subunit, and 
toxoids) has an impact on the stability to heat. Inactivated 
viruses are the most sensitive to heat, while toxoids and 
subunits the least. This is of utmost importance for flu 
vaccines, and research has focused on stabilization by 
drying the solution into solid powder, keeping the efficacy. 
The techniques for the drying are spray drying, freeze-
drying, spray freeze-drying, vacuum, or air-drying [37]. 
The obtained powders are then suitable also for alternative 
administration routes, including dermal, pulmonary, nasal, 
oral, and preventing the needle phobia [37].
The main issue arising when drying a solution containing 
the antigens is the sensitivity of the antigen to heat, cold, 
shear, and dehydration. Thereby, selected protective 
excipients, such as l-leucine, lactose/trehalose, and 
mannitol/dextran, are routinely employed in the formulative 
process. In particular, in the case of a type 5 human 
Adenovirus vector, the combination of excipients preserving 
the best activity after spray drying was mannitol/dextran, 
allowing for storage at room temperature, instead of −80°C 
[39]. The choice of a suitable stabilizer depends on the type 
of vaccine: in two types of recombinant vectors, enveloped 
virus or non-enveloped one, the type of stabilizer giving the 
best effect differed. In presence of a lipidic membrane, in an 
enveloped virus, trehalose resulted in higher protection of 
the virus, due to the formation of stronger hydrogen bonds 
with the lipids of the viral membrane. Conversely, for non-
enveloped adenovirus, mannitol, due to its smaller size, was 
more effective in replacing the water molecules surrounding 
the capsid [40]. Thereby, a careful optimization of the 
formulation parameters in the first stages of the vaccine 
product development should include also the analysis of 
the best excipients to stabilize the antigens in a vitrified 
status. However, the formulation of antigens and adjuvants 
in nanoparticles or microneedles can contribute to solve the 
stability problem, as discussed below.
Present: nanotechnology in vaccine 
development
With the development of nanotechnology, more researchers 
focus their interests in developing nanomaterials as 
promising vaccination methods, not only because 
nanomaterials have controlled properties, such as diameter, 
zeta-potential, surface morphology, and antigens loading 
efficiency, but also due to various nanomaterials triggered 
immune responses by targeted delivery in vivo [41, 42]. 
Different from the conventional vaccines for influenza, 
Fig. 4  Stability of common vac-
cines to freeze and heat stress 
in ordinal scale. a Conventional 
vaccines. b Vaccines newly 
introduced in clinical practice. 
BCG Bacille Carmen Guerin, 
DTP diphtheria–tetanus–per-
tussis, Hep A hepatitis A, 
HepB hepatitis B, OPV oral 
poliomyelitis vaccine, Hib: 
Haemophilus influenza type b, 
HPV human papilloma virus, 
IPV inactivated polio vaccine, 
JE Japanese encephalitis, Men 
A meningitis A, Men PS men-
ingitis polysaccharide, MMR 
measles–mumps–rubella, Penta 
DTP + HepB + Hib, Rotarix® 
and Rotateq® rotavirus vaccine, 
TT tetanus toxoid, Typhim Vi® 
typhoid polysaccharide vaccine 
Reproduced from ref. [38], 
under the terms of the Creative 
Commons Attribution License 
(http://creat iveco mmons .org/
licen ses/by/3.0)
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chickenpox, measles, mumps, and rubella that usually 
contain the inactivated pathogens, nanomaterial vaccines 
(nanovaccines) are mainly involved in subunit vaccines, 
containing only the necessary antigens that trigger the 
targeted immune response [43]. As mentioned above, 
subunit vaccines are safer but less immunogenic than the 
conventional vaccines, due to the lack of the pathogen-
associated molecular patterns (PAMPs); thus, additional 
adjuvant or/and nanomaterial delivery systems are required 
for the full function of the subunit vaccines [44]. An 
important advantage of the nanomaterials is the appropriate 
protection of the antigens within the nanomaterials until 
they reach the targeted area where they are delivered to 
the antigen-presenting cells (APCs) [45]. In other words, 
the appropriate protection of antigens in the nanomaterials 
can decrease the unnecessary immune response caused by 
the exposition of antigens on systemic circulation [46]. 
Moreover, some of the nanomaterials itself can exhibit 
certain immunogenicity when they are internalized by the 
APCs [47].
Several nanomaterial delivery systems have been 
developed as nanovaccines, such as polymer-based 
nanoparticles, metallic nanoparticles, liposomes, 
inorganic nanoparticles, and composited nanoparticles 
[48–52]. Interestingly, not only the composition of these 
nanovaccines, such as the loading adjuvant or antigens, 
affect the immunogenicity, but also the properties of these 
nanovaccines like the diameter, shape, and surface coating 
have an impact on the immune response [53]. In this section, 
the interaction between nanovaccines’ properties and 
immunogenicity, the application of these nanovaccines, and 
their advantages and disadvantages are discussed focusing 
on the continuous development of such systems.
Nanovaccine properties and their effects 
on immunogenicity
Since the size is one of the most important properties in 
nanomaterials, researchers have systematically investigated 
the interaction between the nanovaccines’ diameter and the 
immunogenicity [54, 55]. So far, there are several studies 
showing that nanovaccines with small diameter can be 
more effectively internalized by the APCs than the big 
ones, because the smaller diameter makes them easily 
transported through the epithelia and other biological 
barriers [56]. For example, Gutierro et al. prepared bovine 
serum albumin (BSA)-loaded poly(d,l-lactic-co-glycolic) 
acid (PLGA) nanovaccines with different diameters (200, 
500, and 1000 nm). These nanovaccines were administrated 
(intranasally, orally, or subcutaneously) into BALB/c 
mice. Compared with the free antigen (1 µg, subcutaneous 
administration), the particle groups exhibited slightly 
higher serum total IgG and IgG2a/IgG1 ratio. However, 
the decreasing diameter did not result in increasing 
immunogenicity of PLGA nanovaccines. In addition, the 
1000-nm nanovaccines elicited higher serum IgG antibody 
levels and similar IgG2a/IgG1 ratios compared with the 
smaller ones, which can be due to the enhanced access to 
the APCs and a similar antigen-presentation mechanism. 
Generally, the particle diameters ranging from 20 to 50 nm 
tend to drain to the lymphatic vessels and accumulate in 
the lymph nodes [57]. In addition, Li et al. administrated 
BALB/c mice with various zein particles distinguished 
from different diameter (241.4 to 879.2 nm), doses (200, 
600, 800 µg), and administration route (intramuscular and 
subcutaneous). Interestingly, they found that the particle 
diameter did not have any influence on the immunogenicity 
after three intramuscular injections. The immune response 
generated was long lasting and highly specific. The repeated 
administration induced rapid and strong systemic recall 
immune responses via both intramuscular and subcutaneous 
routes. The immunogenicity of zein nanoparticles can be 
of concern when they are applied as drug delivery systems, 
but this also can be an advantage when they are used as 
nanovaccines [58]. In general, the interactions between 
various particle diameters and the immunogenicity are 
complicated dynamic processes that can also be influenced 
by the administration routes, types of particles, and 
injection doses.
The shape is also an important characteristic for the 
nanovaccines, not only because several studies indicate 
that nanoparticles with different shape can regulate the 
differentiation of immune cells, such as macrophages, but 
also because the shape can influence the biodistribution and 
uptake of nanoparticles in vivo, which can further affect the 
immunogenicity of the nanovaccines. Li et al. found that 
the spherical nanoparticles showed the fastest endocytosis 
rate, followed by cubic nanoparticles, then rod- and disk-
like nanoparticles, as shown in Fig. 5. Through detailed 
free energy analysis, the nanoparticles’ shape effects can 
be attributed to the membrane-bending energy change. The 
spherical nanoparticles exhibited the minimal membrane-
bending energy change, while disk-like nanoparticles 
displayed the maximal membrane-bending energy change. 
Interestingly, star-shaped nanoparticles showed similar 
behavior with the spherical ones in wrapping time and high 
efficacy for drug delivery, which can be interesting to use as 
guidance for the nanovaccine shape [59].
In addition to the internalized rate, other studies have 
focused on the internalization amount and biodistribution. 
Shao et  al. prepared mesoporous silica nanoparticles 
(M-MSNPs) with a various aspect ratio (1, 2, and 4). 
They found that long-rod M-MSNPs exhibited the higher 
internalization amount in both cancer cells and normal cells 
than the short-rod and the sphere-like ones, because of the 
difference in the endocytosis pathways. A clathrin-mediated 
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pathway was involved in the internalization of sphere 
M-MSNPs, while a macropinocytosis-mediated pathway 
was responsible for the uptake of the long-rod M-MSNPs. 
However, there were no significant differences in the 
cytotoxicity and hemolytic rate by M-MSNPs with various 
shapes. As for the biodistribution, through the intravenous 
administration, all M-MSNPs were mainly located in the 
reticuloendothelial system organs, including the liver, 
spleen, and kidney. Specifically, long-rod M-MSPs tended to 
travel to the spleen compared with the sphere-like M-MSNPs 
that were easily trapped in the liver. In addition, the rod-
shaped M-MSNPs preferentially accumulated in tumor 
sites than sphere-like M-MSNPs [60]. The abovementioned 
results indicate that nanoparticle shapes interfere not only 
with the internalization rate and amount but also with the 
biodistribution, which means that the design of nanovaccines 
should systematically consider these interactions.
As another important feature for the nanoparticles, 
surface coating influences not only the hydrophilicity of 
nanoparticles, but also the circulation time and uptake 
efficacy by the phagocytic cells. Therefore, as for the 
nanoparticles developed as nanovaccines, the surface coating 
should be carefully considered. Several studies have focused 
on the interaction between various surface coatings, such as 
poly(ethylene oxide), poly(sarcosine), and hyaluronic acid, 
and the immune system. Many of these studies found that 
the PEGylation of nanoparticles, such as liposomes, and 
micelles can induce the generation of anti-PEG antibody 
by repeated injection in the animals [61]. In addition, 
several PEGylated products also display a decreasing 
therapeutic efficacy and other adverse effects after repeated 
administration in the clinics. Takuya et al. prepared lipid 
nanoparticles with different PEG lengths to investigate 
the relationship between PEG shedding rate and anti-PEG 
antibody production [62]. As reported by the Wilson et al., 
the length of the PEG lipophilic tail is strongly correlated 
with the strength of the anchor that is formed between the 
PEG and the lipid nanoparticle membrane, which means 
that the shorter the PEG acyl chains are, the faster the PEG 
shedding will be [63]. As a result, Takuya et al. found that 
the lipid nanoparticles with short acyl chain (fast-shedding) 
induced less anti-PEG antibody production compared with 
the long acyl chains (slow-shedding). In addition, the slow-
shedding PEG lipid nanoparticle mainly accumulated to the 
Kupffer cells (resident liver macrophages) rather than the 
hepatocytes [57].
In addition to PEGylation, researchers have developed 
poly(sarcosine) and hyaluronic acid as surface coatings 
Fig. 5  Internalization pathway of nanoparticles. a Side view of the 
internalization pathway for PEGylated nanoparticles with grafting 
density 1.6 chains per  nm2. b Top view of the internalization pathway 
for PEGylated nanoparticles with grafting density 0.6 chains per  nm2. 
Reprinted with permission from ref. [59]
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of nanoparticles to increase their hydrophilicity and 
investigated the interaction between these polymers and 
immunogenicity. Cheol et al. found that the nanoparticles 
with a long hydrophilic chain of pol (sarcosine) exhibited 
main accumulation on the B1a cells and the production 
of the class-switched antibody immunoglobulin G 3 
(IgG3). In addition, the antigenicity of poly(sarcosine) and 
nanoparticle properties influenced the generation of IgG3 
and immunoglobulin M (IgM) by different methods [64]. 
This result was beneficial for immunotherapy applications 
via antibody-dependent cell-mediated cytotoxicity. In 
contrast, with the antigenicity of poly(sarcosine), Abdulaziz 
et al. prepared chitosan nanoparticles (CS NPs), hyaluronic 
acid–coated nanoparticles (HA-CS NPs), and alginate-
coated nanoparticles (Alg-CS NPs) [65]. They found that 
HA modification significantly reduced the protein adsorption 
on the surface of the nanoparticles. A following gene 
ontology analysis further confirmed that HA-CS NPs were 
the less immunogenic one compared with the CS NPs and 
Alg-CS NPs. Interestingly, two unique anti-inflammatory 
proteins (inter-alpha-trypsin inhibitor heavy chain and alpha-
1-acid glycoprotein) were found in the protein coronas of 
the HA-CS NPs, but not in the Alg-CS NPs and CS NPs. 
In addition, a pro-inflammatory protein (Clusterin) was not 
found on the protein coronas of HA-CS NPs, but in the CS 
and Alg-CS nanoparticles.
Different nanoparticle surface coatings can lead to 
a difference in the composition of the protein corona, 
which can further contribute to the immunogenicity of 
nanoparticles, such as the pro-inflammatory surface coating 
or the anti-inflammatory coating. Therefore, when these 
nanoparticles are developed in nanovaccines systems, the 
surface coating and potential protein corona components 
should be carefully investigated.
Application of nanovaccines
Inspired by the unique properties of nanovaccines, such 
as co-delivery of antigen and adjuvant in the same carrier, 
controlled release of adjuvant, activated targeting ability, 
and passive targeting to the lymph nodes with nanoparticles 
diameter at 20–50  nm, researchers have developed 
nanoparticles as nanovaccines for various applications, such 
as cancer immunotherapy and infectious disease.
When nanovaccines are applied for cancer 
immunotherapies, there are two main approaches in fighting 
against cancer cells: cell-mediated and humoral immunity 
[66, 67]. As for the cell-mediated immunity, the sequence of 
events starting with the activation of APCs, antigen process, 
and priming, proliferation and differentiation of T cells is the 
base for the effective immune function. Gao et al. prepared 
whole tumor cell lysates (from B16 melanoma cells) loaded 
nanovaccines modified with the mannose moieties (for 
targeting the dendritic cells). More than twofold increase 
in antigen uptake and maturation of bone marrow–derived 
dendritic cells (BMDCs) were observed in the BMDCs 
co-cultured with nanovaccines compared with the control 
group (BMDCs without any treatment). Furthermore, the 
nanovaccines also exhibited potent anti-tumor capability 
in vivo: ca. 35% of target melanoma cells were lysed by the 
effector T cells in the mice immunized with the nanovaccines 
compared with only ca. 12% in the control group [68].
In addition to the whole tumor cell lysates, tumor-
related peptides are one of the most important resources 
for the antigens. Zeng et al. encapsulated the melanoma 
antigen peptide tyrosinase–related protein 2 (Trp2) as 
an antigen and toll-like receptor-9 (TLR-9) agonist CpG 
oligodeoxynucleotides (CpG ODN) as an adjuvant into a 
nanovaccine platform. After formulation optimization, 
their nanovaccines can target proximal lymph nodes and the 
cargo can be effectively internalized into the dendritic cells. 
Additionally, the nanovaccines significantly expand (more 
than twice compared with the free Trp2 and CpG ODN) 
the antigen-specific cytotoxic T lymphocytes (CTLs) and 
display anti-tumor efficacy in a lung metastatic melanoma 
model (C57BL/6 mice) [69].
Cell membrane–based biomimicking strategies provide 
more options to the construction of nanovaccines, since the 
cancer cell membranes contain plenty of tumor-specific 
protein that can be used as antigens in the composition of 
nanovaccines. In addition, some proteins on the surface of 
APCs cell membranes, such as costimulatory molecules, 
can also participate in the immune response. Specifically, 
our group recombined cancer cell membranes (4T1 cells) 
with monophosphoryl lipid A and a commercial lipid to 
formulate the nanovaccine liposomes (vacosomes) [70]. 
The vacosome-enhanced BMDC maturation (∼75% for 
the vacosomes and ∼13% for the untreated BMDCs) and 
anti-tumor ability (∼20% cell viability of 4T1 treated with 
the vacosomes) in vitro. Besides developing vacosomes, 
we also developed cancer cell membrane (MDA-MB-231 
cells) coating thermally oxidized porous silicon (core 
structure) coated with acetalated dextran (shell structure) 
nanovaccines [71]. After stimulation with our nanovaccines, 
both the immortal cell lines and peripheral blood monocytes 
(PBMCs) expressed the co‐stimulatory signals (CD80 
and CD86). Moreover, the nanovaccines enhanced the 
secretion of interferon (IFN)‐γ in PBMC and did not 
induce the secretion of IL‐4, which further promoted the 
polarization of the newly primed T cells toward a Th1 
cell–mediated response. Additionally, we also observed 
inhibited melanoma tumor progression on mice immunized 
twice with the complete nanovaccine formulation in our 
further investigations [72]. Moreover, some researchers 
also attempted to fuse living cell and get the hybrid cell 
membranes. For example, Ma et  al. fused the BMDCs 
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(activated by lipopolysaccharides, LPS) with cancer 
cells (MC38 cells) [73]. In this way, the whole tumor-
associated antigens and costimulatory molecules, such as 
CD80 and CD86, and major histocompatibility complex 
(MHC) II can present in the same fused cell. The authors 
isolated and purified the fused cell membrane and coated 
PLGA nanoparticles with these cell membranes (named 
as DMNPs in this article). As a result, they found that the 
fused cell membrane enhanced the accumulation of DMNPs 
in the spleen and lymph nodes and further elicited the T 
cell response. Finally, the DMNPs also exhibited potential 
efficacy in cancer prevention and in inhibiting cancer 
regression.
Besides the fusion of living cells to get the hybrid cell 
membranes, Yao et al. attempted to engineer the cancer cell 
to express a co-stimulatory marker B16-CD80/Ovalbumin 
(OVA) cell by transduction, and then isolate the engineering 
cell membranes [74]. Furthermore, they prepared the PLGA 
nanoparticles coated with engineering cell membranes as 
artificial antigen-presenting cells (aAPCs). As a result, 
tumor antigen-specific immune responses and priming of 
T cells were observed in both prophylactic and therapeutic 
models (C57BL/6 mice challenged with B16-OVA cells).
Considering the safety and simple production, genetic 
nanovaccines, such as messenger RNA (mRNA) and 
deoxyribonucleic acid (DNA) nanovaccines, have been 
widely investigated in the treatment of cancer. For example, 
Rein et  al. prepared a nanovaccine system containing 
nucleoside-modified antigen-encoding mRNA (encoding 
tumor antigens), glycolipid antigen, and α-galactosylceramide 
(activation of invariant natural killer T cells, iNKT cells). 
A broad set of antitumor effector cells was promoted, 
including CTLs, iNKT cells, and NK cells, while reducing 
local immune suppression at the tumor site. Additionally, 
by combination with programmed cell death protein 1/
programmed death-ligand 1 (PD-1/PD-L1) checkpoint 
inhibition, the nanovaccines can prevent the induction of 
iNKT anergy and overcome adaptive resistance at the tumor 
site [75]. Liu et al. generated a DNA nanodevice vaccine by 
precisely assembling two types of molecular adjuvants and 
an antigen peptide within the inner cavity of a tubular DNA 
nanostructure [76]. The nanovaccines opened the lysosomes 
in APCs exposing adjuvants and antigens to activate a strong 
immune response. A potent antigen-specific long-term T-cell 
response was observed in the B16-OVA and B16F10 tumor 
murine models after treatment with the nanovaccines.
As a result of the flexible compositions, nanovaccines also 
exhibit potential capability in controlling infectious diseases. 
For example, Kamal et  al. prepared a self-assembling 
protein nanoparticle (SAPN)-containing five  CD8+ human 
leukocyte antigen (HLA)-A03-11 supertype-restricted 
epitopes from antigens expressed during Toxoplasma 
gondii’s lifecycle, the universal  CD4+ T cell epitope Pan 
DR epitope (PADRE), and flagellin as a scaffold and TLR5 
agonist, as shown in Fig. 6 [77]. After immunization with 
the protein nanovaccines, HLA-A*1101 transgenic mice 
showed effective IFN-γ responses and activated  CD8+ T 
cells in fighting against Toxoplasma gondii.
Currently, there is still no Food and Drug Administration 
(FDA)-approved vaccines for the Yersinia pestis. Danielle 
et al. developed polyanhydride nanoparticle-based vaccines 
recombining cyclic dinucleotides and F1-V that can induce 
protection against pneumonic plague [78]. All the mice 
immunized with nanovaccines were protected from Yersinia 
pestis lethal challenge within 14 days post-immunization. In 
addition, after a single dose of nanovaccines, 75% of mice 
were still protected from a challenge even after 182 days 
of immunization with high levels of antigen-specific serum 
IgG, which demonstrated the rapid and long-lived protective 
immunity caused by the nanovaccine immunization.
The seasonal flu epidemics still annually cause severe 
illness and death around the world. Although the seasonal 
flu vaccine is updated annually according to the epidemic 
prediction and influenza surveillance data, if it mismatched 
with the circulating strains, the vaccines will be ineffective. 
Ding et al. prepared universal vaccines based on the highly 
conserved ectodomain of influenza matrix protein 2 (M2e) 
that were further inserted into capsid protein of porcine 
circovirus type 2 (PCV2) [79]. This nanovaccine induced 
high levels of M2e‐ and PCV2‐specific immune responses 
and protected mice from a lethal challenge of swine, human, 
and influenza A virus.
In conclusion, biomimetic nanovaccines are more efficient 
vaccine formulations because of their unusual transport 
kinetics, antigen profiles, immunostimulatory properties, 
and targeting skills.
The future of vaccine formulations
Historically, vaccine formulation assumes that they practice 
equal immunogenicity and offer protection exclusively 
against their target pathogen regardless of the target 
population. However, vaccinations can have off-target 
effects, and the immunogenicity of the vaccine can differ 
significantly with demographic factors, such as age and 
sex. For example, epidemiological studies indicate that the 
value of Bacille Calmette-Guérin (BCG) vaccination can 
differ according to the formulation of BCG and the age of 
administration to optimize both unique and heterologous 
beneficial effects with optimum timing in early life. Overall, 
BCG is a precise vaccinology paradigm that will help set a 
standard for next-generation vaccines [80].
Recent developments in biomaterials present new 
possibilities for enhancing the efficacy of next-generation 
vaccines. Most current vaccine technologies are poorly 
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immunogenic, have only intermittent protection, or generate 
chances of regaining pathogenicity. Strong collaborative 
efforts among researchers in different fields would lead to 
new biomaterials with improved properties. New physical 
and chemical structures would play critical roles in vaccine 
safety, cellular trafficking, and overall immune response 
[81].
The COVID-19 pandemic caused by the SARS-CoV-2 
virus is a clear warning that new infectious diseases with 
pandemic potential can inflict high human and economic 
losses. In response to the crisis, regulatory agencies have 
made unprecedented strides to help get safe and reliable 
vaccinations to the market sooner [82]. Leaders must invest 
in evidence-based vaccine delivery strategies that generate 
demand, allocate, and distribute vaccines. Verifying 
coverage is essential to have a widely immunized population 
[83]. Researchers have previously studied the difficulties 
of supplying communities with life-saving equipment or 
drugs. The phenomenon of “implementation bottlenecks” 
is a leading cause of the inability to convert recognized 
measures into robust service delivery [84]. It is fundamental 
to establish a rigorous communication strategy to encourage 
vaccine uptake, particularly in communities that we would 
imagine will be reluctant or reject vaccination [85]. 
Industries are essential collaborators in all attempts to plan 
for and best adapt to epidemics, pandemics, and emerging 
infectious diseases. Therefore, the global community has 
an opportunity to build on this momentum to design a 
sustainable model for vaccines [82].
A new vaccine delivery platform: 
microneedles
Microneedle technology
In this review, we assessed vaccines as a vital component 
of pandemic preparedness. Insufficient manufacturing 
capability can hinder its production and delivery. 
Also, there is a strong need to establish technologies 
to reduce the antigen dose, since lower vaccine antigen 
doses led to better T cell responses. In  vitro studies 
showed a close relationship between antigen dose and 
functional avidity of CD8 T cells. Recent data have 
confirmed this relationship for CD4 and CD8 T cells 
after vaccination in both animals and humans [86]. 
Fig. 6  Mode of action of SAPN NPs. SAPN adjuvanted with glucopyranosyl lipid adjuvant–stable emulsion (GLA-SE) has peptides that are pre-
sented by MHC molecules on the follicular dendritic cells to T lymphocytes. Reprinted with permission from Ref. [77]
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The exploration of such dose-saving strategies requires 
alternate routes for the administration of vaccines, such 
as intradermal. Conventional vaccine injection bypasses 
the skin’s immune system and introduces the antigen 
into the muscle or subcutaneous tissue where there is no 
detectable resident APC population. However, the skin is 
an anatomical area with greater immunogenicity capacity 
due to the presence of many of epidermal Langerhans 
cells and dermal dendritic cells [87]. A Phase I trial was 
performed by Combadière et  al. to prove intradermal 
superiority relatively to intramuscular. The transcutaneous 
delivery of the inactivated influenza vaccine resulted in 
a more effective induction of influenza-specific CD8 + T 
cell responses relative to that administered through the IM 
route [88]. Despite the advantages and substantial research 
efforts, transdermal vaccine delivery has yet to reach its 
full potential as an alternative to hypodermic injections 
[89].
An obvious obstacle to injections is needle phobia. 
Survey reports that ~25% of parents and more than 60% of 
children have reported fear of needles, a significant barrier 
to vaccination [90]. Since MNs are short and narrow 
enough to prevent dermal nerve stimulation, there is no pain 
associated with administering vaccines through this route 
[91]. MN-based patches aim to resolve the need to deliver 
drugs with ease of oral administration and effectiveness 
equal to injection [92]. MNs measure hundreds of microns 
and are administered in the skin, which is 1–2 mm thick 
at specific administration sites, overcoming the outermost 
skin barrier layer, the stratum corneum, and providing 
transient pathways for minimally invasive transcutaneous 
delivery. Specifically, an array of MNs is attached to a 
backing, permitting bandage-like application. Therefore, 
administering of vaccines through the skin using MNs would 
present a cost-effective, quick, and secure solution without 
trained personnel (Fig. 7) [93].
Microneedle (MN) vaccination provides a superior 
immunological response at the same dose. Several studies 
have found higher antibody production and better cellular 
response using MNs compared with hypodermic injections 
[94–96]. Using a very dense array of MNs may enhance 
the immunological response. More significant damage to 
cells in the epidermis would increase the immunogenic 
signal, leading to further savings in vaccine dosage. By 
reducing antigen exposure to protein-damaging stresses 
during traditional microparticle fabrication/antigen 
encapsulation, antigen stability can be favorably preserved 
[97]. Existing MNs address skin-resident dendritic cells 
directly; antigens distributed by MNs are taken-up by skin 
dendritic cells and transported for antigen presentation to the 
cutaneous draining lymph nodes [93, 98]. As recent studies 
have shown, the latter is a problem, since these dendritic 
Fig. 7  Possible benefits of MN 
vaccine implementation in 
developing countries
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cells are relatively inefficient in antigen transport, as less 
than 1% of the injected antigen enters lymph nodes [99]. 
An alternative approach can be to deliver antigens where 
they can be drained to lymph nodes and activate lymph 
node–resident dendritic cells. The dermis layer of the 
skin is highly perfused with lymphatic capillary networks. 
Consequently, directly targeting vaccines to lymph nodes 
following intradermal delivery via MNs seems plausible 
[100]. In a study related to MN protein delivery, Harvey 
et al. conducted imaging studies using reporter dyes showing 
rapid lymphatic-mediated uptake [101].
MN improves vaccine compliance and can improve 
safety by minimizing the production of harmful medical 
waste, inhibiting disease transmission through needle 
reuse and needle-based accidents. The latest research 
has shown the effectiveness of MNs for stratum 
corneum reliable and pain-free disruption, encouraging 
transcutaneous delivery of a broad spectrum of vaccine 
components [102, 103]. It is critical, though, to perform 
further research into adverse reactions and side effects, to 
gain full understanding of the long-term consequences of 
polymer deposition in the skin. Although repetitive long-
term vaccine delivery applications are unnecessary, there 
is the need to thoroughly elucidate polymer deposition 
effects. Polymer deposition can result in polymer 
accumulation in the tissue, causing local erythema or 
developing granuloma or accumulation in the body’s 
clearance organs [104].
A potential advantage of MNs is that they would reduce 
the expertise needed for administration, because they are 
pressed to the skin by hand or using a specific applicator 
(Fig. 8) [92, 105]. Self-administration is not appropriate in 
some cases, but administration by less-trained personnel 
would still boost access to vaccines, especially in developing 
countries [92, 106].
Another issue in these countries is vaccine wastage. For 
example, sometimes only a portion of the doses is used 
before the vaccine expires. It can also happen that health 
care personnel decides not to vaccinate a patient, because 
doing so would require opening a new vaccine vial when 
there are not enough patients to use the entire vial [92, 108]. 
Avoiding these complications is possible by using disposable 
single-dose MNs. The “cold chain” is a further core aspect 
when delivering vaccines from the point of manufacturing 
to the point of use. The cold chain is a costly method to store 
and distribute vaccines at recommended temperatures to 
preserve vaccine potency. The estimated cost of cold chain 
storage is $200–300 million annually, and vaccine shortages 
frequently result from this infrastructure’s deficiencies [109].
Although maintaining the cold chain is expensive, it 
is crucial in supplying vaccines to distant clinics in hot 
climates served by poorly developed transport networks 
[38]. MNs can have improved stability without refrigeration, 
in part because of their solid-state nature [92]. Mistilis et al. 
demonstrated that a MN-based vaccine for influenza can be 
stable at least 6 months at 25°C and at least a few weeks at 
40°C [110]. Other studies had similar results with different 
formulations [111, 112].
Lyophilized vaccines are much more amenable to 
long-term storage and more resistant to temperature 
extremes and humidity. Freeze-drying might therefore 
help in conditions where maintaining the cold chain is 
difficult, but the solid phase must then be followed by a 
reconstitution back into a ready-for-injection liquid form. It 
is a delicate procedure that requires specialized personnel 
to avoid errors that could have severe consequences on 
patients’ health. On the contrary, MNs do not need to be 
reconstituted, as they use the fluids of the skin to deliver 
the molecules [113]. MNs still need conditions to maintain 
drug activity, integrity, and sterility. Packaging plays a 
considerable role in providing chemical, physical, and 
mechanical protection [92].
All the mentioned positive attributes of MNs must 
be rigorously evaluated and addressed to translate the 
technology into clinical usage. End-user adoption of this 
technology must be measured, understood, and modified 
to incorporate users’ needs [114]. A recent literature 
review analyzed MN vaccination technology perception 
and acceptance, especially in the pediatric population. The 
findings revealed favorable views of the general population 
and health care practitioners’ technology, mentioning several 
benefits widely associated with this technique. Even so, 
Fig. 8  MNs for influenza vacci-
nation. a MNs contain an array 
of 100 MNs measuring 650 μm 
tall that is mounted on an adhe-
sive backing. b MNs are manu-
ally administered to the wrist, 
enabling self-administration by 
study participants Reproduced 
with permission from Ref. [107]
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there were questions of unfamiliarity with the technology 
and ability to ensure accurate delivery of vaccines [115].
A current issue is that majority of MN studies took place 
on a laboratory scale. In order to scale-up the production, 
new approaches to manufacturing need to be developed, and 
further financial investments from large pharmaceutical are 
needed over the coming years. Dose loading capability must 
also be discussed for the manufacturing considerations of 
MNs so that the vaccine manufacturer can integrate the 
technology into its processes [116]. Centrifugation is still 
used by most laboratories, but automatic nanodispensers 
or other faster methods may be a more adequate solution 
for industries. For example, a team developed a new kind 
of female mold, namely, a double-penetration female mold 
(DPFM). DPFM has the pinpoints covered by a waterproof 
breather membrane that has proven helpful in reducing 
the effect of gas resistance and viscosity of the solution. 
For the scale-up fabrication of dissolving MNs, a positive-
pressure microperfusion technique (PPPT) based on 
DPFM was proposed [117]. Finally, establishing uniform 
approval requirements and standards for good manufacturing 
practice, permitting MN characterization and eventual 
commercialization, is essential [118].
MNs have many excellent features, such as the ability to 
cross the stratum corneum without pain, minimal invasiveness, 
and the ability to skip the first-pass metabolism. Such benefits 
make MNs outstanding candidates for immunological 
biomolecule delivery [119].
MN‑based formulation
Solid MNs generate micropores in the skin, and after removal 
of the MNs, a patch is applied, allowing the drug in the patch 
to diffuse. Disconnected treatments can be an incommodious 
process, and intradermal injection of the vaccine was more 
effective than solid MNs [113]. For these reasons, our review 
will not focus on solid MNs, but on the most used MNs 
for vaccines: coated and dissolving. Dissolving MNs are 
the most advanced and complex, as they can encapsulate 
vaccines within their matrix [120], while the MN shaft and 
tip sizes constrain the delivery of vaccines via coated MNs 
[121]. Both types use biocompatible polymers and exploit 
the fluids present in the skin for dissolution to deliver the 
payload. In coated MNs, only the coating dissolves, while 
in dissolving MNs, the MNs dissolve entirely, leaving the 
backing intact and with no sharp residual [113]. However, 
the small size of MNs tips usually restricts dosing to less 
than 10 mg and ideally less than 1 mg. The bright side is that 
vaccine doses are typically less than 0.1 mg [92].
The most common technique for manufacturing polymer 
MNs includes using an inverse mold, usually made of 
polydimethylsiloxane. The protocol consists of casting the 
polymer solution and drying it within the mold. The last 
stage is to peel MNs off from the mold after drying [122]. 
The choice of materials for the MNs must satisfy multiple 
parameters, such as the need to be sufficiently strong to 
puncture the skin and be acceptable for manufacturing 
processes using current good manufacturing practice. In 
other examples, MNs are made of swellable hydrogels that 
release the encapsulated drug upon gel hydration [92]. Arya 
et al. used dissolving MNs to administer rabies DNA vaccine 
to dogs. They administered the patches manually, and the 
MNs dissolved in the skin in about 15 min [123]. Another 
study used a coating of PLGA-PLL/γPGA nanoparticles to 
deliver an Ebola DNA (EboDNA) vaccine. The resulting 
coated MNs showed a higher EboDNA loading and greater 
mechanical strength than the ones with a naked EboDNA 
coating [124].
MN‑based applications
In the previous section, we mentioned examples of DNA 
vaccines, but the compatibility of MNs goes way beyond 
this; it has also been proven with subunit, virus-like 
particles, live-attenuated, and inactivated vaccines. For 
example, MN-soluble glycoprotein subunit vaccines are 
another possible approach to achieve protection against the 
lethal Ebola virus [125]. Zhu et al. encapsulated enterovirus 
71 (EV71) recombinant virus-like particles in MNs, to 
investigate the immune responses against EV71 infection 
[126]. Fabricated MNs dissolved and released payload 
rapidly within 2 min of application, and the punctured skin 
displayed just mild erythema that healed rapidly 24 h after 
treatment with MNs. More specifically, immunization tests 
in mice have shown that tenfold lower antigen dose–loaded 
EV71 MNs produced intense immune responses and 
defensive efficacy comparable with traditional IM injection.
Live-attenuated viruses are unstable above 8°C, so a cold 
chain is necessary, making them pricey [127]. This represents 
an appealing case for the application of MNs. One study 
demonstrated that intradermal administration of live-attenuated 
herpes zoster vaccine resulted in increased varicella-zoster 
virus-specific antibody production at the same dosage of 
subcutaneous injection [128]. The same study hypothesized 
that mild inflammation following intradermal vaccination 
might increase the adaptive immune response’s efficiency. 
However, the research is based on a limited sample size and 
has found no significant cell-mediated immunity variations 
[129]. Erdos et  al. instead found a more robust cellular 
immune response, using polyinosinic acid, polycytidylic acid 
as an adjuvant in combination with an adenovirus-encoded 
antigen. Lastly, a clinical trial with inactivated influenza 
vaccine delivered by MNs was conducted in humans [107]. 
MNs were well tolerated, well accepted and result in robust 
immunological responses whether administered by healthcare 
workers or by the participants themselves (Fig. 9). These 
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findings showed that MN vaccination could be an exciting new 
method to increase the present-day availability of vaccines and 
reduce immunization costs.
The spectrum of pathogen vaccines tested with MNs 
is also quite broad and includes bacteria, protozoa, and 
viruses. A limited number of studies have investigated 
MN vaccination against bacteria. Live-attenuated Bacille 
Calmette-Guerin (BCG) bacillus is the only tuberculosis-
preventive vaccine approved worldwide to date. This specific 
vaccine must be delivered intradermally, causing severe skin 
inflammation and, sometimes, permanent scars. Chen et al. 
developed MNs with an internal “cave” to accommodate and 
release the powder BCG vaccine into the intradermal space 
[130, 131]. The approach managed to avoid any adverse 
reaction, achieving an immune response comparable to IM 
vaccination. Based on a previous publication, which provided 
an essential proof-of-concept regarding the delivery of non-
toxoid bacterial antigens [132], Pastor et al. conducted a 
study for MN vaccination against Shigellosis [131]. To 
further prove the MN-based technology’s versatility, a group 
developed a dissolving MNs device called MicroHyala and 
tested its efficacy against tetanus and diphtheria, malaria, 
and influenza [133]. The findings indicated effective immune 
responses against all infectious diseases. Researchers have 
also investigated the use of MNs to deliver alternative and 
model vaccine agents, in addition to the delivery of vaccines 
currently in use. A study proved that delivering DNA 
vaccines might provide a promising approach to cancer 
immunotherapy. The group loaded a synergistic nanopolyplex 
cocktail on dissolving MNs, succeeding in highly efficient 
use of this non-invasive and straightforward delivery system, 
overcoming the weaknesses of traditional injections [134].
Moreover, the use of MNs has been investigated by 
researchers working on a possible vaccine against the current 
coronavirus causing the COVID-19 pandemic. It is unlikely 
that the industry will decide to bet on a new technology 
immediately after a new vaccine approval, but it cannot be 
ruled out that MNs may be used for future generations of 
COVID-19 vaccines. Using the existing experience with 
MERS-CoV vaccines, Kim et al. performed the first study 
Fig. 9  Solicited reports of adverse events 7  days after vaccination 
and serological response to study drug administration. a Local and 
systemic adverse events associated with vaccination are shown in 
different groups. IIV inactivated influenza vaccine, 7 days after vac-
cination, MNP microneedle patch, HCW health-care worker, IM 
intramuscular. b Hemagglutination inhibition GMTs (log 2), sero-
conversion, and seroprotection against A/Christchurch/16/2010 
(NIB-74 [H1N1]), A/Texas/50/2012 (NYMC X-223 [H3N2]), and B/
Massachusetts/2/2012 (NYMC BX-51[B]) strains for  MNPIIV-HCW, 
 MNPIIV-self,  MNPplacebo, and  IMIIV 28  days after vaccination. Bars 
show 95% CI. GMT geometric mean titers, IIV inactivated influenza 
vaccine, MNP microneedle patches, HCW health care worker, IM 
intramuscular Reproduced with permission from ref. [107]
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on a possible MN COVID-19 vaccine with SARS-CoV-2 S1 
subunit vaccines [135]. MN-based patches were added to the 
skin of mice, collecting serum at various times. By week 2, 
the group observed elevated levels of virus-specific IgG. The 
gamma-irradiation sterilization of the patches did not affect 
immunogenicity. MN delivery of coronaviruses-S1 subunit 
vaccines is a promising immunization strategy against 
coronavirus infection.
Overall, it is indisputable that the skin, the largest 
organ in the human body, has become an attractive 
vaccine delivery site. The large number of publications 
and new groups studying MNs is further evidence of this 
technology’s enormous potential for vaccine delivery. In 
particular, MNs seem to offer possible solutions to face 
vaccine formulations’ biggest problem that is maintaining 
vaccine component stability, both during manufacture 
and during storage. There is no doubt that further clinical 
vaccination studies in human volunteers are needed to 
demonstrate safety and to prove the efficacy of this vaccine 
approach further. However, there is great optimism in the 
scientific community regarding the significant impact 
that vaccine-loaded polymeric MNs may have on global 
health. Both scientific and technological efforts will enable 
quicker responses to emerging pandemics [136].
Conclusions
With the advent of new health conditions that cannot be 
addressed by traditional methods, it has become necessary 
to explore new areas regarding vaccination. The advantages 
offered by nanoparticles’ proprieties have been widely 
exploited in the formulation of new vaccines. Several 
clinical studies have proven their efficiency in enhancing 
both cellular and humoral immune responses. The 
possibility of formulating vaccines in the dry state remains 
one of the most coveted objectives, because it would allow 
circumventing the need for the cold chain. A dry formulation 
and the possibilities of reducing the number of qualified 
personnel are two of the primary reasons for the scientific 
community’s interest in microneedle-based vaccines. 
Although clinical trials have begun, there is still a need to 
expand the number and variety of patients, and to develop 
a technology that has a broad spectrum of applicability. 
Therefore, it is undeniable that future vaccination depends 
on the success of research in developing long-term 
preservable vaccines, easily administrable, and guarantees 
a strong and lasting immune response.
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